Ipsen S.A. (OTCMKTS:IPSEY – Get Rating) has been given a consensus rating of “Hold” by the eleven analysts that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $106.67.
A number of research analysts have recently commented on the company. Barclays increased their price target on Ipsen from €88.00 ($92.63) to €95.00 ($100.00) and gave the company an “underweight” rating in a research note on Thursday, April 14th. UBS Group raised Ipsen from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 11th. Credit Suisse Group upped their price objective on Ipsen from €87.00 ($91.58) to €105.00 ($110.53) and gave the company a “neutral” rating in a research note on Friday, March 25th. AlphaValue upgraded shares of Ipsen to a “reduce” rating in a research report on Thursday, February 17th. Finally, Bryan, Garnier & Co lowered shares of Ipsen from a “buy” rating to a “neutral” rating in a report on Wednesday, April 27th.
Shares of OTCMKTS:IPSEY opened at $25.27 on Friday. Ipsen has a one year low of $21.71 and a one year high of $32.51. The firm has a 50 day simple moving average of $29.25 and a 200 day simple moving average of $26.61.
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents.
- Get a free copy of the StockNews.com research report on Ipsen (IPSEY)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.